Searchable abstracts of presentations at key conferences in endocrinology

ea0041oc8.2 | Thyroid - Translational | ECE2016

Selenium modulates apoptosis in thyroid follicular cells: characterization of molecular mechanisms

Cristina Nettore Immacolata , Maione Luigi , Passaro Carmela , Pivonello Claudia , Negri Mariarosaria , Desiderio Silvio , De Nisco Emma , Pivonello Rosario , Ungaro Paola , Portella Giuseppe , Colao Annamaria , Emidio Macchia Paolo

: Inflammation and several oxidative processes are modulated by Selenium (Se) trough the selenoproteins. Se deficiency has been associated with thyroid autoimmune diseases and hypothyroidism, while Se-supplementation reduces antibodies titles and ameliorates ultrasound pattern of the gland.Aim of the current study, is to study the molecular effects of Se-supplementation in thyroid follicular cells (FRTL5).FRTL5 cells have been star...

ea0041gp17 | Adrenal (1) | ECE2016

Improved evening and nocturnal cortisol exposure time profile in patients with adrenal insufficiency treated with dual release hydrocortisone: correlation with improvement in metabolic profile

Simeoli Chiara , Ferrigno Rosario , De Martino Maria Cristina , Auriemma Renata Simona , Pivonello Claudia , Negri Mariarosaria , Iacuaniello Davide , Di Gennaro Gilda , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (GCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), with a significant impact on morbidity and mortality. Possible explanations are supra-physiological doses and impaired cortisol profile. In particular, elevated evening cortisol levels were related to glucose tolerance and insulin sensitivity alterations and visceral obesity. Once-daily-dual-release-hydrocortisone (OD-DR-HC), better reproducing the physiological ...

ea0041ep599 | Endocrine tumours and neoplasia | ECE2016

Dual targeting of PIK3/AKT/mTOR and IGF1/KRAS/BRAF pathways in an in vitro model of ovarian cancer: strategies for cell proliferation control

de Angelis Cristina , Galdiero Giacomo , Pivonello Claudia , Patalano Roberta , Bifulco Giuseppe , Di Spiezio Sardo Attilio , Alviggi Carlo , De Placido Giuseppe , Colao Annamaria , Pivonello Rosario

Ovarian cancer (OC) is the most lethal gynecological cancer. Debulking surgery and platinum-based chemotherapy are the cornerstone of OC management; however, after a partial initial response, tumors invariably relapse. Therapeutic approaches should account for interindividual heterogeneity since OC histiotypes show distinct genetic profile. A2780 cell line has been annotated as high grade serous ovarian cancer (HGSOC); nevertheless, recent research underlined that the genetic ...

ea0041ep620 | Endocrine tumours and neoplasia | ECE2016

Potential role of the adrenolitic drug mitotane in the treatment of hepatocarcinoma (HCC): effect on cell proliferation in HCC cell lines

Pivonello Claudia , Provvisiero Donatella Paola , Negri Mariarosaria , Di Gennaro Gilda , De Angelis Cristina , Simeoli Chiara , Patalano Roberta , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

HCC is one of the most common malignancies worldwide. Local approaches are generally preferred for patients whose disease is restricted to the liver. In patients with extrahepatic disease systemic therapy can be considered. Chemotherapy did not demonstrate convincing survival advantages in several trails for HCC patients. Presently, the kinase inhibitor sorafenib is the only approved systemic target therapy for the treatment of advanced HCC. Mitotane (dichlorodiphenildichloroe...

ea0041ep628 | Endocrine tumours and neoplasia | ECE2016

Potential role of vitamin D in restoring sensitivity to mTOR inhibitors in hepatocellular carcinoma (HCC): 1,25(OH)vitamin D (VITD) reverts everolimus (EVE) resistance in a HCC cell line

Pivonello Claudia , Provvisiero Donatella Paola , Negri Mariarosaria , Di Gennaro Gilda , De Angelis Cristina , Galdiero Giacomo , Simeoli Chiara , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

HCC is a difficult-to-treat- cancer with poor prognosis. The recent EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced HCC resistant to sorafenib treatment. In selected patients, the well-established antitumor effect of EVE could make this drug a potential adjuvant therapy. Unfortunately, the acquired resistance to this molecule due to the tumor adaptation to chronic drug use is a current challe...

ea0041ep712 | Male Reproduction | ECE2016

The role of dopamine pathway on human sperm: in vitro effect of dopamine receptor agonists and antagonists on sperm motility, kinetics and viability

de Angelis Cristina , Cariati Federica , Galdiero Giacomo , Coppola Giorgio , Galdiero Mariano , Salzano Ciro , Pivonello Claudia , Patalano Roberta , Alviggi Carlo , De Placido Giuseppe , Colao Annamaria , Pivonello Rosario

Dopamine has been found in both semen and oviductal fluid and dopamine receptors (DRs) have been detected in male genital tract and spermatozoa, suggesting that dopamine system may control important reproductive functions in humans. Dopamine improves sperm motility and viability in animal models, although the underlying molecular mechanisms have not been fully elucidated. The aims of this study were to investigate DRs expression in human spermatozoa and to evaluate the in ...

ea0037gp.19.08 | Pituitary–Acromegaly | ECE2015

Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly

Auriemma Renata S , Grasso Ludovica F S , Galdiero Mariano , Pivonello Claudia , Salzano Ciro , Negri Mariarosaria , Angelis Cristina de , Colao Annamaria , Pivonello Rosario

Somatostatin analogues (SA) are known to revert acromegalic cardiomyopathy mainly in young patients with short disease duration, whereas pegvisomant (PEG) reportedly improves cardiac structure and performance in patients resistant to SA. To date, no data are available on the effects of long-term SA+PEG on cardiovascular complications. The current study aimed at investigating the effects of long-term SA+PEG on cardiac structure and performance in acromegaly. Thirty-six acromega...

ea0037ep48 | Adrenal cortex | ECE2015

The treatment with ‘dual release' hydrocortisone (DR-HC) in congenital adrenal hyperplasia: short-term (6 months) and long-term (12 months) follow-up after the switch from conventional glucocorticoids to DR-HC

Simeoli Chiara , De Martino Maria Cristina , Iacuaniello Davide , Mannarino Teresa , Cozzolino Alessia , De Leo Monica , Pivonello Claudia , Negri Mariarosaria , De Angelis Cristina , Colao Annamaria , Pivonello Rosario

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, life-long glucocorticoid (GC) treatment is often required to replace cortisol deficiency and to avoid the ACTH-dependent androgen levels increase. However, in these patients, the multiple daily doses required with conventional GCs can cause cortisol overexposure, leading to an increased risk of metabolic syndrome (MS), an impaired quality of life (QoL), and poor treatment compliance (TC). T...

ea0035oc7.3 | IGF-1 and Thyroid Basic | ECE2014

Targeting the insulin-like growth factor 1 (IGF1R) and insulin (IR) receptor with a dual IGF1R/IR inhibitor, OSI-906, to potentiate mTOR inhibitor effects in experimental models of hepatocellular carcinoma (HCC)

Pivonello Claudia , Negri Mariarosaria , De Martino Maria Cristina , de Angelis Cristina , Napolitano Maria , Izzo Francesco , Colao Annamaria , Hofland Leo J. , Pivonello Rosario

The mTOR and IGF/insulin pathways are frequently dysregulated in HCC. Antitumoral activity of mTOR inhibitors (mTORi) has been demonstrated in experimental models but in early clinical studies mTORi alone have shown modest antitumoral activity. IGF/insulin-dependent Akt activation, via IGF1R and IR, has been suggested as potential mechanism for mTORi resistance. This study aimed at evaluating the expression of mTOR and IGF/insulin pathway components and the effects of mTORi al...

ea0070aep10 | Adrenal and Cardiovascular Endocrinology | ECE2020

Cortisol rhythm in patients with adrenal insufficiency switched from conventional glucocorticoids to dual release hydrocortisone: Impact on metabolic profile

Simeoli Chiara , Iacono Marina , Ferrigno Rosario , Negri Mariarosaria , Pivonello Claudia , Simona Auriemma Renata , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

Background: Several evidences suggested that conventional glucocorticoids (CGCs) used as replacement treatment in adrenal insufficiency (AI) are inadequate to mimic physiological cortisol circadian rhythm (CCR), and that CCR disruption, represented by non-physiological pattern of peaks and troughs and elevated evening GC levels, might be responsible for the increased metabolic and, consequently, cardiovascular risk. It has been demonstrated that once daily dual-release-hydroco...